Proactive Research analyst Ed Stacey presents his research on Mydecine Innovations Group ((NEO: MYCO) (OTCMKTS: MYCOF) a biotech company developing new treatments for mental health conditions, from natural sources, including psychedelic compounds.
Stacey explains Mydecine's unique differentiators, their telemedecine platform and their two drug programs which target PTSD and nicotine addiction. But worth noting IP protection.
He says the firm will leverage the expertise of a medical and scientific team that includes world-renowned practitioners in psychiatry and psychopharmacology.
The company also benefits from a strong network of external relationships with academic research partners and with companies specialised in delivering on pharmaceutical developments.